
FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra
pharmafile | October 4, 2019 | News story | Medical Communications, Sales and Marketing | AstraZeneca, FDA, Fasenra, pharma
AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra (benralizumab) in a pre-filled, single-use auto-injector form, known as the Fasenra Pen.
The decision was based on Phase 1 and 3 data from two separate trials, and follows the product’s approval in the EU. Fasenra is currently approved in the US, EU, and Japan as an add-on treatment for eosinophilic asthma.
Data from these trials indicated that 97% of administrations in the 120 at-home patients, conducted by either the patients themselves or their caregiver, were successful at weeks 12 and 16. Furthermore, it was demonstrated that 96% of the auto-injectors that were returned were still functional at weeks 12 and 16.
“Fasenra is the only respiratory biologic that can be given every eight weeks after the initial loading-dose period,” explained Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca. “Today’s news means we can now offer Fasenra in an even more convenient way, giving US healthcare providers and patients the option of administering Fasenra at home or in a doctor’s office, and making treatment more accessible to patients with severe eosinophilic asthma.”
Matt Fellows
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …






